AU2004247034A1 - Immunotherapeutics for biodefense - Google Patents

Immunotherapeutics for biodefense Download PDF

Info

Publication number
AU2004247034A1
AU2004247034A1 AU2004247034A AU2004247034A AU2004247034A1 AU 2004247034 A1 AU2004247034 A1 AU 2004247034A1 AU 2004247034 A AU2004247034 A AU 2004247034A AU 2004247034 A AU2004247034 A AU 2004247034A AU 2004247034 A1 AU2004247034 A1 AU 2004247034A1
Authority
AU
Australia
Prior art keywords
antibody
group
antibody fragment
seq
sequence selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004247034A
Other languages
English (en)
Inventor
Katherine S. Bowdish
Shana Frederickson
Toshiaki Maruyama
Mary Jean Nolan
Martha A. Wild
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of AU2004247034A1 publication Critical patent/AU2004247034A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1278—Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2004247034A 2003-06-02 2004-05-26 Immunotherapeutics for biodefense Abandoned AU2004247034A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/452,593 2003-06-02
US10/452,593 US20040258699A1 (en) 2002-02-11 2003-06-02 Immunotherapeutics for biodefense
PCT/US2004/016557 WO2004110362A2 (en) 2003-06-02 2004-05-26 Immunotherapeutics for biodefense

Publications (1)

Publication Number Publication Date
AU2004247034A1 true AU2004247034A1 (en) 2004-12-23

Family

ID=33551270

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004247034A Abandoned AU2004247034A1 (en) 2003-06-02 2004-05-26 Immunotherapeutics for biodefense

Country Status (9)

Country Link
US (1) US20040258699A1 (https=)
EP (1) EP1648487A2 (https=)
JP (1) JP2006526639A (https=)
KR (1) KR20060031803A (https=)
CN (1) CN1829525A (https=)
AU (1) AU2004247034A1 (https=)
CA (1) CA2527843A1 (https=)
IL (1) IL172231A0 (https=)
WO (1) WO2004110362A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1395657B1 (en) * 2000-12-05 2007-04-18 Wisconsin Alumni Research Foundation Receptor for bacillus anthracis toxin
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
WO2004052277A2 (en) * 2002-12-05 2004-06-24 Wisconsin Alumni Research Foundation Anthrax antitoxins
WO2005007804A2 (en) * 2003-04-10 2005-01-27 President And Fellows Of Harvard College Anthrax conjugate vaccine and antibodies
CA2560759A1 (en) * 2004-03-03 2005-12-22 Iq Corporation Human anthrax toxin neutralizing monoclonal antibodies and methods of use thereof
CA2591665C (en) * 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
US7838252B2 (en) * 2005-02-17 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating a subject having an anthrax toxin mediated condition
WO2008063147A2 (en) * 2005-03-31 2008-05-29 The General Hospital Corporation Anthrax polypeptide binding
AU2006245734C1 (en) 2005-05-12 2012-05-24 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
US20070202117A1 (en) * 2005-12-22 2007-08-30 Herman Groen Compositions and Methods Of Modulating the Immune Response
US7794732B2 (en) 2006-05-12 2010-09-14 Oklahoma Medical Research Foundation Anthrax compositions and methods of use and production
WO2007141274A2 (en) * 2006-06-06 2007-12-13 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
US8093360B2 (en) 2006-09-28 2012-01-10 Elusys Therapeutics, Inc. Antibodies that bind B. anthracis exotoxin, formulations thereof, and methods of use
EP1913955A1 (en) 2006-10-19 2008-04-23 Gerhard, Markus Novel method for treating H.pylori infections
EP2246426A4 (en) * 2008-01-29 2011-08-10 Inst Antibodies Co Ltd COMPOSITION FOR THE NEUTRALIZATION OF BOTULINUS TOXIN TYPE-A AND HUMAN ANTIBODIES AGAINST BOTULINUS TOXIN TYPE-A
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
GB0812316D0 (en) * 2008-07-07 2008-08-13 Secr Defence Antibody
US8343495B2 (en) * 2009-01-10 2013-01-01 Auburn University Equine antibodies against Bacillus anthracis for passive immunization and treatment
CN103172734A (zh) * 2013-04-07 2013-06-26 中国人民解放军南京军区军事医学研究所 人源抗炭疽毒素保护性抗原中和抗体Fab及应用
TWI606834B (zh) * 2014-10-24 2017-12-01 國立陽明大學 缺氧培養之間葉幹細胞用於修復血管內皮細胞的應用
CN104628853B (zh) * 2015-02-06 2017-10-10 中国人民解放军南京军区军事医学研究所 人源抗炭疽保护性抗原PA的抗体IgG及其应用
WO2018232144A1 (en) * 2017-06-14 2018-12-20 Monojul, Llc High-affinity anti-human folate receptor beta antibodies and methods of use
CN109134647B (zh) 2018-08-28 2020-08-04 东莞市朋志生物科技有限公司 Ns1蛋白的结合蛋白
CN109081869B (zh) 2018-08-28 2022-06-03 东莞市朋志生物科技有限公司 Ns1蛋白的结合蛋白
MX2024000957A (es) * 2021-07-22 2024-02-08 Us Gov Sec Navy Anticuerpos de dominio unico que se unen y neutralizan el virus de la encefalitis equina venezolana.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2407443A1 (en) * 2000-05-04 2001-11-08 President And Fellows Of Harvard College Compounds and methods for the treatment and prevention of bacterial infection
JP2006503547A (ja) * 2002-02-11 2006-02-02 アレクシオン ファーマシューティカルズ， インコーポレイテッド 生物兵器防衛のための免疫療法

Also Published As

Publication number Publication date
EP1648487A2 (en) 2006-04-26
CN1829525A (zh) 2006-09-06
IL172231A0 (en) 2006-04-10
JP2006526639A (ja) 2006-11-24
KR20060031803A (ko) 2006-04-13
US20040258699A1 (en) 2004-12-23
CA2527843A1 (en) 2004-12-23
WO2004110362A3 (en) 2005-07-28
WO2004110362A2 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
US20040009178A1 (en) Immunotherapeutics for biodefense
US20040258699A1 (en) Immunotherapeutics for biodefense
US8299218B2 (en) Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
AU2006322445B2 (en) Anti-orthopoxvirus recombinant polyclonal antibody
Amersdorfer et al. Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries
RU2764740C1 (ru) Биспецифическое антитело против вируса бешенства и его применение
EP2134749B1 (en) Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US7700738B2 (en) Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
CN112225813B (zh) 针对破伤风毒素的抗体及其用途
CA2492883C (en) Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
Yu et al. Neutralizing antibodies of botulinum neurotoxin serotype A screened from a fully synthetic human antibody phage display library
KR101958312B1 (ko) 보툴리눔 a형 독소에 대한 항체
CN115260306B (zh) 靶向SARS-CoV-2受体结合基序的单克隆抗体及其识别抗原表位和应用
Chen et al. Synthetic antibodies in infectious disease
JP2023106636A (ja) ヒト抗破傷風毒素抗体
HK1152339A (en) Composition for neutralizing botulinus toxin type-a, and human anti-botulinus toxin type-a antibody

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period